RBC Capital raised the firm’s price target on Fulcrum Therapeutics (FULC) to $10 from $7 and keeps a Sector Perform rating on the shares. The company presented first look at the 20 mg dose cohort of Phase 1b PIONEER trial at ASH, and while the data are still maturing, the 9.9% HbF boost compares favorably to the 5.6%/8.6% shown by the 12 mg dose, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Fulcrum Therapeutics Reports Positive Phase 1b Trial Results
- Fulcrum Therapeutics price target raised to $23 from $16 at Piper Sandler
- Fulcrum Therapeutics price target raised to $25 from $18 at H.C. Wainwright
- Fulcrum announces results from 20 mg dose cohort of Phase 1b PIONEER trial
- Fulcrum Therapeutics initiated with a Buy at Truist